PubRank

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

Clinical Trial ID NCT01363232

PubWeight™ 31.91‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01363232

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011 5.82
2 Melanoma: new insights and new therapies. J Invest Dermatol 2012 1.54
3 Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget 2014 1.34
4 Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget 2014 1.33
5 Beyond BRAF: where next for melanoma therapy? Br J Cancer 2014 1.26
6 Pathways and therapeutic targets in melanoma. Oncotarget 2014 1.17
7 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
8 NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene 2012 1.15
9 BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther 2015 0.99
10 Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015 0.97
11 Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmgenomics Pers Med 2012 0.89
12 Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers. Int J Mol Sci 2015 0.88
13 Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review. Chemother Res Pract 2012 0.87
14 Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol 2016 0.87
15 Treatment of NRAS-mutant melanoma. Curr Treat Options Oncol 2015 0.86
16 Targeting genomic alterations in squamous cell lung cancer. Front Oncol 2013 0.85
17 Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. Clin Cancer Res 2014 0.85
18 Discovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical Modeling. PLoS Comput Biol 2015 0.84
19 Targeting pathways downstream of KRAS in lung adenocarcinoma. Pharmacogenomics 2014 0.82
20 Targeting the PI3K pathway for cancer therapy. Future Med Chem 2012 0.82
21 Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials. Curr Oncol 2012 0.81
22 Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco Targets Ther 2016 0.81
23 Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer. Curr Colorectal Cancer Rep 2016 0.78
24 Targeted Therapies in Melanoma: Translational Research at Its Finest. J Invest Dermatol 2015 0.78
25 MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy. Drug Des Devel Ther 2015 0.77
26 Transcriptional regulation of autophagy in RAS-driven cancers. J Clin Invest 2015 0.76
27 Therapeutic Approaches to RAS Mutation. Cancer J 2016 0.76
28 Targeting mutant NRAS signaling pathways in melanoma. Pharmacol Res 2016 0.75
29 Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer. Pancreas 2016 0.75
30 The pharmacogenomics of drug resistance to protein kinase inhibitors. Drug Resist Updat 2016 0.75
Next 100